13 completed. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
Follow Arteritis: new trials by email Literature Review of Arteritis trials Research Report on Arteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c. - Giant Cell Arteritis | Phase 3 | Completed | Novartis Pharmaceuticals | 151 | 2022-09-29 | 2026-02-27 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) Secukinumab 300 mg, Placebo, Secukinumab 150 mg - Giant Cell Arteritis (GCA) | Phase 3 | Completed | Novartis Pharmaceuticals | 354 | 2021-10-06 | 2026-03-31 |
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO treatment - Arteritis, Giant Cell, Blindness and Low Vision | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2020-02-04 | 2026-06-18 |
| MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Prednisone treatment, Tocilizumab treatment, Methotrexate treatment - Giant Cell Arteritis | Phase 3 | Completed | Centre Hospitalier Universitaire Dijon | 230 | 2020-01-27 | 2026-10-30 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Upadacitinib, Corticosteroid (CS), Placebo - Giant Cell Arteritis (GCA) | Phase 3 | Completed | AbbVie | 429 | 2019-01-24 | 2026-02-24 |
| An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Tocilizumab - Giant Cell Arteritis | Phase 3 | Completed | Hoffmann-La Roche | 3 | 2017-10-25 | 2020-09-04 |
| Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis MMF, CYC, Glucocorticoids - Takayasu Arteritis | Phase 3 | Completed | Chinese SLE Treatment And Research Group | 138 | 2017-03-16 | 2023-08-30 |
| Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Tocilizumab - TAKAYASU ARTERITIS | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 18 | 2014-06-10 | 2020-08-19 |
| An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Tocilizumab, Prednisone, Tocilizumab Placebo - Giant Cell Arteritis | Phase 3 | Completed | Hoffmann-La Roche | 251 | 2013-07-22 | 2020-02-06 |
| Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) corticosteroid and azathioprine, corticosteroid and placebo - MPA, PAN or EGPA With FFS=0 | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 114 | 2008-05-01 | 2025-09-12 |
| HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis adalimumab, placebo - Giant Cell Arteritis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 69 | 2006-05-01 | 2012-07-10 |
| Hydroxychloroquine in Giant Cell Arteritis hydroxychloroquine/placebo - Giant Cell Arteritis | Phase 3 | Completed | University Hospital, Toulouse | 75 | 2002-01-01 | 2015-10-06 |
| Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Alendronate versus alfacalcidol (1-alpha OH vitamin D) - Rheumatoid Arthritis, Polymyalgia Rheumatica | Phase 3 | Completed | UMC Utrecht | 200 | 2000-05-01 | 2006-11-29 |
Giant Cell Arteritis (10) · Vasculitis (3) · Polymyalgia Rheumatica (2) · Takayasu Arteritis (2) · Arthritis, Rheumatoid (1) · Blindness (1) · Churg-Strauss Syndrome (1) · Granulomatosis with Polyangiitis (1) · Microscopic Polyangiitis (1) · Polyarteritis Nodosa (1) · Polymyositis (1) · Rheumatic Diseases (1) · Vascular Diseases (1) · Vision, Low (1)
Cardiovascular Diseases (13) · Skin Diseases (13) · Skin Diseases, Vascular (13) · Skin and Connective Tissue Diseases (13) · Vascular Diseases (12) · Autoimmune Diseases (11) · Brain Diseases (11) · Central Nervous System Diseases (11) · Cerebrovascular Disorders (11) · Immune System Diseases (11) · Nervous System Diseases (11) · Autoimmune Diseases of the Nervous System (10) · Vasculitis (10) · Vasculitis, Central Nervous System (10)
Adrenal Cortex Hormones (3) · tocilizumab (3) · secukinumab (2) · Adalimumab (1) · Azathioprine (1) · Blood Specimen Collection (1) · Glucocorticoids (1) · Hydroxychloroquine (1) · Methotrexate (1) · Prednisone (1) · Surveys and Questionnaires (1) · Therapeutics (1) · upadacitinib (1)
Assistance Publique - Hôpitaux de Paris (3) · Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Centre Hospitalier Universitaire Dijon (1) · Centre Hospitalier Universitaire de Nice (1) · Chinese SLE Treatment And Research Group (1) · UMC Utrecht (1) · University Hospital, Toulouse (1)
France (10) · Germany (4) · Belgium (3) · Canada (3) · Denmark (3) · Italy (3) · Netherlands (3) · Norway (3) · Portugal (3) · Spain (3) · Sweden (3) · United Kingdom (3) · United States (3) · Australia (2) · Austria (2)
Loic Guillevin, MD, PhD (1) · Xavier Mariette, MD, PhD (1) · Xinping Tian, MD (1)
PMID 10068416, PMID 16221103, PMID 16914703, PMID 17332971, PMID 17407214, PMID 17557758, PMID 20054700, PMID 23528439, PMID 23897775, PMID 27924855, PMID 28678392, PMID 28745999, PMID 30786937, PMID 30835950, PMID 31056661, PMID 32943098, PMID 34049857, PMID 34718434, PMID 36963127, PMID 38279390, PMID 38840219, PMID 40174237, PMID 42234457
2016 (1), 2017 (1), 2023 (1)